Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0N7LA
|
|||
| Former ID |
DIB012609
|
|||
| Drug Name |
BIBH 1
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 2 | [1] | |
| Company |
Boehringer Ingelheim
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Prolyl endopeptidase FAP (FAP) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02198274) Intravenous BIBH 1 in Patients With Metastatic Colorectal Cancer. U.S. National Institutes of Health. | |||
| REF 2 | A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res. 2003 May;9(5):1639-47. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.